Cambrex acquired the 35,000 square foot High Point site from PharmaCore in October 2016, since which time it has announced a series of investments to increase capacity.
The contract development and manufacturing organization (CDMO) produces active pharmaceutical ingredients (APIs) and intermediates in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III at the site.
Announced earlier this week, the most recent expansion brings Cambrex’s total investment in the facility to more than $5m.
The expansion required the sourcing, acquisition, installation, and qualification of more than 20 new analytical instruments, including HPLCs, mass spectrometers, and support equipment, according to the company.
Additionally, as part of the investment, Cambrex plans to hire 12 new analytical scientists.
“The addition of this new facility further expands our capabilities in method development and qualification and validation, to ensure successful project development in the short term, and allowing efficient technical transfer of projects to commercial scale in the future,” said Brian Swierenga, VP, operations and site director for Cambrex High Point in a press release.
“This expansion is part of Cambrex’s on-going strategic plan to increase development capacity and resources in North America,” he added.